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Testicular germ cell tumours are the commonest tumours of young men and are broadly managed either as pure seminomas or as
‘nonseminomas’. (e management of Stage 1 nonseminomatous germ cell tumours (NSGCTs), beyond surgical removal of the
primary tumour at orchidectomy, is somewhat controversial. Cancer-speciﬁc survival rates in these patients are in the order of
99% regardless of whether surveillance, retroperitoneal lymph node dissection, or adjuvant chemotherapy is employed. However,
the toxicities of these treatment modalities diﬀer. Undertreating those destined to relapse exposes them to the potentially
signiﬁcant toxicities of 3-4 cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. Conversely, giving adjuvant
chemotherapy to all patients following orchidectomy results in overtreatment of a signiﬁcant proportion.(erefore, the challenge
lies in delineating the patient population who require adjuvant chemotherapy and in determining how much chemotherapy to
give to adequately reduce relapse risk. (is chapter reviews the factors to be considered when adopting a risk-adapted strategy for
giving adjuvant chemotherapy in Stage 1B NSGCT sand discusses the data regarding the number of BEP cycles to administer.
1. Background
Testicular germ cell tumours (TGCTs) are the commonest
tumours of youngmen aged between 20 and 35 years.(ey are
divided into those of pure seminoma subtype (that histo-
logically resemble primordial germ cells) and those with ele-
ments that resemble extra embryonic tissue (with or without
seminoma components), generally termed “nonseminomas.”
Nonseminomatous germ cell tumours (NSGCT) make up
roughly 50% of cases and are common in a younger age group
than seminomas (median age around 25 years). A charac-
teristic of TGCT is their sensitivity to cisplatin-based che-
motherapy which means that, in contrast to most solid
tumours, patients with metastasis are usually cured. (e most
commonly used schedule is “BEP,” consisting of bleomycin,
etoposide, and cisplatin. (is is highly successful chemo-
therapy and will cure around 85–90% of patients with meta-
static disease and over 95% of those with good prognostic
features (i.e., absence of visceral metastasis and low tumour
markers) [1]. (e cost of this is the risk of signiﬁcant toxicity,
both acute and late (e.g., renal damage, peripheral neuropathy,
hearing damage, increased risk of cardiovascular disease, and
second cancer; summarised in Table 1). Management of these
patients is supported by monitoring tumour markers such as
alpha fetoprotein (AFP) and human chorionic gonadotrophin
(HCG), which are elevated in patients withmetastatic NSGCT
in around two-thirds of cases [2].
Around 75–80% of patients diagnosed with NSGCT
present with no other clinical evidence of disease outside the
testis on examination, imaging, or on tumour markers.
(ese patients are termed Stage I and have excellent out-
comes, with 5-year disease-speciﬁc survival over 98% [3].
Without additional treatment though, relapse occurs in
around 30%.
Histopathologicalmarkers have been used to help predict
the risk of recurrence. (e best validated of these prognostic
markers has been the presence or absence of lymphovascular
invasion (LVI). Patients without LVI have around 15–20%
risk of relapse, and if LVI is present, there is a 40–50% risk of
recurrence [4]. (is ﬁnding has been consistent across
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a number of large studies and is current standard of care in
dividing patients into higher risk groups despite the modest
predictive power; that is, even in low-risk group, 15–20% of
patients will relapse and 50%of high-risk patients will remain
in remission [1].
Other markers such as proportion of embryonal
carcinoma (EC), rete testis invasion, and MIB-1 staining
have been proposed, but results have not been fully vali-
dated. Tumours with no embryonal components generally
have a low rate of recurrence [5–7].Absenceofundiﬀerentiated
embryonal carcinoma was one of the original MRC risk
factors identiﬁed in the ﬁrst MRC surveillance studies [6].
Some studies have suggested that the proportion of embry-
onal carcinoma may increase relapse risk [4, 8] though this
does correlate with LVI and so has not been fully validated.
MIB-1has also been suggested to be associatedwith increased
relapse risk, but in a recent study [8], an association could not
be validated. Recently, CXCL12 expression has been pro-
posed as a prognostic marker and validated in two data sets.
On the basis of this marker and vascular invasion, three risk
groups have been proposed including low (10% risk), in-
termediate (30–40% risk), and high (70%) risk groups though
this remains to be validated.
A number of diﬀerent approaches have been utilised in
this patient group. In the past, removing the retroperitoneal
lymph nodes has been practiced particularly in the United
States and parts of Europe. Patients who are node negative
(pN0) have a lower rate of subsequent recurrence (∼10–
15%). Node-positive patients (pN1) may be cured by this
approach but continue to have a signiﬁcant rate of re-
currence (∼30%). (ese patients have often been oﬀered
subsequent adjuvant chemotherapy (see below). (ough
undoubtedly some patients may avoid chemotherapy, this is
at the cost of a major surgical procedure with the risk of
attendant morbidity both immediate and long term. Patients
still require follow-up as there remains a signiﬁcant risk of
relapse even in the pN0 group, and even without the use of
adjuvant chemotherapy, a substantial number of patients
will still be exposed to chemotherapy.
An alternative approach, based on pioneering work
of Peckham and colleagues and subsequent MRC trials is
to watch patients closely a policy termed active surveil-
lance. (is approach watches carefully with the aim of early
relapse detection and treatment of recurrence by BEP
chemotherapy. (is approach has the virtue of avoiding
treatment (and its attendant toxicities) except when nec-
essary.(e use of surveillance has grown over the years but is
not necessarily trouble free. Patients who relapse require the
use of full-dose chemotherapy [3]. (e surveillance phase
can cause psychological stress and can make it diﬃcult for
some patients to return to a normal lifestyle for fear of
recurrence. Finally, there remains a concern regarding
compliance. Several studies have shown a degree of non-
compliance with follow-up in GCT patients. (e fear is that
noncompliers can relapse with more advanced disease with
a poorer prognosis.(is is a concern as a priori identiﬁcation
of noncompliance is diﬃcult. For these reasons, the role of
adjuvant chemotherapy has been explored especially in
those at high risk of recurrence.
2. Adjuvant BEP Chemotherapy
An alternative approach to surveillance is to use adjuvant
chemotherapy following treatment.(is was ﬁrst explored in
the early 1990s after the success of using BEP chemotherapy
in metastatic disease. It was argued that using more limited
chemotherapy in those at high risk would restrict exposure to
chemotherapy and prevent relapse. (e key study of this ap-
proach was the MRC TE05 study. 114 patients were recruited
with a predicted recurrence risk based on MRC risk factors
of >50% [9]. Two patients recurred but one patient on
histology review was proven to have a non-germ cell cancer,
so in the 108 patients with centrally reviewed NSGCT, 1
relapsed and the 95%CI excluded a risk of relapse of 5%.(is
studywas supported by similar smaller studies fromBern and
Vienna [10, 11].(ese data have been replicated in a number
of reported studies totalling almost 1000 patients and
a combined risk of relapse of <2% (summarised in Table 2).
Most of the studies have used BEP for adjuvant treatment
though a few studies have used variants of BEP. MD Anderson
reportedonsubstitutingcarboplatin for cisplatin [12], and the
MRC replaced etoposidewith vincristine [13], both achieving
results similar to that achieved by BEP. (e lower eﬃcacy of
carboplatin in metastatic disease and concerns regarding
neurotoxicity, respectively, has meant that these approaches
have not been adopted.
Following this work, adjuvant BEP has become an option
for high-risk stage 1 NSGCT. Its use has been the subject of
Table 1: Toxicities of BEP chemotherapy.
Dose-related toxicities of BEP Non dose related Unknown relationship to dose
Infertility Febrile neutropenia Second malignancy
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much debate. (is is centered on the issue of late toxicity
from BEP. (e acute toxicities of BEP (Table 1) have been
recognised for many years. Over the last decade, the risk of
long-term eﬀects have been better appreciated especially
neuropathy, cardiovascular disease, and second malignancy.
(is has meant that opponents of adjuvant chemotherapy
have advocated avoiding exposure of patients to the hazards
of chemotherapy unless there is evidence of deﬁned disease.
On the other hand, proponents of adjuvant chemotherapy
point to the lower doses used, and assuming this means less
risk of toxicity. (ey also note the beneﬁt of lower use of
retroperitoneal lymph node surgery. Originally, the 2 cycles
of BEP used adjuvantly was half of the dose of that used for
metastatic disease. So, with a ∼50% relapse risk, the total
number of cycles of chemotherapy needed to be delivered
(“burden” of chemotherapy) was similar with either ap-
proach, though distributed diﬀerently in the population.
However, with a MRC/EORTC randomised trial [12]
showing that 3 cycles of BEP was suﬃcient for most patients,
the balance in terms of burden of chemotherapy was in
favour of a surveillance approach (i.e., assuming a 50%
relapse risk); for every 100 adjuvant patients, 200 cycles of
BEP would be delivered compared to 150 cycles for 100
surveillance patients undergoing 50 relapses. (is has led to
the exploration as to whether less adjuvant chemotherapy
may be suﬃcient.
3. Single-Cycle Adjuvant BEP
At the Royal Marsden, we initially investigated a single cycle
of BEP in patients with intermediate risk of recurrence. In 22
patients with approximately 20% risk of recurrence (i.e., 4-5
patients expected to recur), no active recurrences were noted
though 1 patient required resection for teratoma diﬀerenti-
ated [20]. In a similar higher risk group (deﬁned as presence
of vascular invasion or predominant embryonal carcinoma)
in 42 patients, Westermann and colleagues reported a single
active relapse compared to an expected rate of around 15
patients [21] (updated in [22]).
(is approach has now been tested in 3 larger studies
(Table 3). In the ﬁrst of these, Albers and colleagues in the
German germ cell cancer study group conducted a rando-
mised trial comparing a single cycle of BEP versus RPLND
[23]. In 191 patients randomised to BEP, 2 relapses were seen
(1 ofwhichwasmature teratoma). In theRPLNDarm, 32/173
patients were node positive and received adjuvant chemo-
therapy, and 15 node-negative patients relapsed (equating to
47 patients with active disease, 27%). (e Scandinavian
Swenoteca [24] group adopted a single cycle of BEP for in-
termediate- and high-risk patients as a population-based
treatment protocol. In their latest report on 571 patients
and a median follow-up of 7.9 years, 3.2% of patients with
lymphovascular invasion (n� 258) and 1.6% patients with no
lymphovascular invasion (n� 255) have relapsed with only
one patient dying of multiply relapsed TGCT.
(e latest study to report is the UK 111 study [25]. (is
large prospective nonrandomised study was designed to
speciﬁcally exclude a relapse risk of over 5% after a single
cycle of BEP. (is study recruited 246 patients and reported
after a median follow-up of 39.9 months and with a mini-
mum follow-up of 2 years in 91% of patients. Four patients
have had a malignant recurrence and 3 a TD recurrence.(e
primary end point was 2-year malignant recurrence rate
which was 1.3% (95% CI 0.4–4.0%) and thus met its aim to
exclude a 2-year recurrence rate of 5%. A full publication is
awaited.
Table 2: Studies of 2 cycles of adjuvant chemotherapy in testicular nonseminomatous germ cell tumours.
Study Institution Chemotherapy Eligibility Median follow-up(months) N
Number of malignant
relapses (all relapses)
Cullen et al. [9] MRC, UK BEP MRC >50% risk NS 104 1 (1)
Pont et al. [11] Vienna BEP VI 79(range, 27 to 119) 40 1 (2)
Bohlen et al. [10] Berne BEP/PVB ≥pT2/EC 93(range 32 to 146). 58 0 (1)
Germa-Lluch et al. [14] Spanish germcell group BEP (90%) ≥pT2 NS 168 1
Chevreau et al. [15] Toulouse BEP VI or EC 113.2(range 63–189) 40 0
Oliver et al. [16] Anglia, UK BEPBOP MRC >30% risk NS 2874 1 (1)2 (2)
Amato et al. [12] MD Anderson CEB ∗MDA high risk 38 68 0 (1)
Guney et al. [17] Istanbul BEP ∗MDA high risk 26(range 10–60) 71 3 (4)
Dearnaley et al. [13] MRC, UK BOP VI 70 115 2 (2)
Bamias et al. [18] Hellenic germcell group BEP ≥pT2/EC 79 142 1 (1)
Mezvrishvili and
Managadze [19] Tbilisi BEP/EP VI NS 41 0 (1)
Total 949 12 (17)1.3% (1.8%)∗MDA high risk: pre-op AFP> 80 ng/ml, VI or >pT2. Chemotherapy drugs: B, bleomycin; C, carboplatin; E, etoposide; O, vincristine; P, cisplatin; V,
vinblastine. MRC, Medical Research Council; VI, lymphovascular invasion present; EC, embryonal carcinoma.
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4. Current Perspectives
It is our opinion that the data discussed are now robust
enough to conclude that 1 cycle of BEP can successfully
reduce the risk of recurrence to less than 5%. (e additional
beneﬁt of adding a second cycle in terms of risk reduction of
relapse is small and, in our judgement, is not suﬃcient to
justify the additional toxicity. Using a single cycle of BEP
would reduce the overall use of chemotherapy in the “high-
risk” vascular invasion population. Using the model de-
scribed above, treating 100 patients with single-cycle ad-
juvant BEP would give 100 cycles to this population
compared to 150 cycles if it is assumed that 50% relapse on
surveillance. In addition to amount of chemotherapy, the
balance of who receives is very diﬀerent either spread across
the whole population or concentrating, with greater expo-
sure, in those with proven disease. (ere is no evidence in
any of the studies of adjuvant chemotherapy or surveillance
that use of either approach aﬀects overall survival. (is has
prompted a vigorous debate between supporters [26–28] of
adjuvant chemotherapy and surveillance as to the optimal
approach, both in seminoma and nonseminoma. To our
mind, to exclusively oﬀer either approach, given lack of
survival diﬀerence, is inappropriate. We attempt to present
a balanced argument of the pros and cons of the two ap-
proaches stressing the impact on relapse and discussing what
is known regarding immediate- and long-term toxicity
(including risk of cardiovascular disease and second ma-
lignancy). (e idea of adjuvant toxicity seems intrinsically
attractive to many, with the wish to get treatment over with
and avoid future uncertainty of relapse as common levers for
deciding on adjuvant chemotherapy.
4.1. Future Approaches. Adjuvant chemotherapy has usually
been used for patients found to be at higher risk of re-
currence. (e adoption of single-cycle adjuvant chemo-
therapy raises the question of whether patients with lower
risk should be oﬀered this treatment. (e Swenoteca group
allowed patients with lower risk of recurrence to receive
adjuvant BEP in their protocols and reported a less than 2%
relapse risk [24]. We do not oﬀer this approach routinely as
this would expose 80% or more of patients to BEP who
would not have relapsed and increases the overall burden of
chemotherapy. (ere may be exceptional instances such as
when surveillance or full course of BEP would be diﬃcult
when it might be considered.
(e landscape of adjuvant therapy could be changed if
there was better prognostication. We recently reported
a new prognostic index that could split stage 1 NSGCT
patients into 3 broad groups based on vascular invasion and
whether they had expression of CXCL12 or had near 100%
embryonal content [8]. Using these criteria, we identiﬁed
a small group (10–15%) with a very high recurrence risk
(>70%) and a signiﬁcant group (∼40–50%) with a low risk of
recurrence (∼10%) with the remainder having a 30–40%
recurrence risk. (is index needs further validation but may
have implications for decision making regarding adjuvant
therapy. We believe most clinicians would agree the low-risk
group should be surveyed and the high-risk group would
beneﬁt from adjuvant therapy. (e intermediate group may
be more controversial.(e total burden of chemotherapy for
surveillance and adjuvant chemotherapy would be roughly
similar. (ese patients might reasonably be surveyed but
many may consider the risk high enough to justify adjuvant
chemotherapy if a single cycle of BEP is used.
(is landscape is not static. More sophisticated genetic
proﬁling may be on the horizon [29], and whilst data are
emerging, that microRNA analysis may be a sensitive in-
dicator of subclinical disease [2, 30]. Any impact on prog-
nostication may aﬀect the balance between surveillance and
adjuvant therapy.
It is possible that the increasing conﬁdence in the use of
adjuvant BEP could change the treatment algorithm in other
areas. For instance, could single-cycle BEP with less-invasive
surgical techniques lead to a resurgence of surgical man-
agement of low-volume (stage 2) NSGCT [31]?
5. Conclusion
Single-cycle BEP is eﬀective at reducing the risk of re-
currence of stage 1 NSGCTto less than 5% and should be the
preferred over two cycles of BEP if adjuvant therapy is
chosen rather than surveillance. However, surveillance ap-
proaches can legitimately still be oﬀered to all patients.
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Gilbert (RMH) [20] 1 or 2 MRC RF 120 22 0 (1) 20% 4
Westermann (Switzerland)
[21]
VI+>50% EC 99 1329 1 30% 13




VI− 95 258255 7 (8)3 (4) 42%12% 10831
111 study [25] VI+ 40 236 4 (7) 42% 99
Total 1004 16 (23)1.6% (2.3%) 305
∗
∗23/305 equals 7.5% of predicted relapses.
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